mitotane
{{Short description|Chemical compound}}
{{Use dmy dates|date=June 2024}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
| verifiedrevid = 462252859
| IUPAC_name = (RS)-1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
| image = Mitotane.svg
| width = 225
| image2 = Mitotane-(2S)-enantiomer-from-xtal-3D-bs-17.png
| chirality = Racemic mixture
| tradename = Lysodren
| Drugs.com = {{drugs.com|monograph|mitotane}}
| MedlinePlus = a608050
| DailyMedID = Mitotane
| pregnancy_category =
| routes_of_administration = By mouth
| ATC_prefix = L01
| ATC_suffix = XX23
| ATC_supplemental =
| legal_CA = Rx-only
| legal_CA_comment = {{cite web | title=Product monograph brand safety updates | website=Health Canada | date=7 July 2016 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html | access-date=3 April 2024}}
| legal_EU = Rx-only
| legal_EU_comment = {{cite web | title=Lysodren EPAR | website=European Medicines Agency | date=12 June 2002 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren | access-date=27 June 2024}}
| legal_status = Rx-only
| bioavailability = 40%
| protein_bound = 6%
| metabolism =
| metabolites =
| elimination_half-life = 18–159 days
| excretion =
| IUPHAR_ligand = 6957
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 53-19-0
| PubChem = 4211
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00648
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4066
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 78E4J5IB5J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00420
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1670
| synonyms = 1,1-(Dichlorodiphenyl)-2,2-dichloroethane; o,p'-DDD
| C=14 | H=10 | Cl=4
| SMILES = Clc1ccccc1C(c2ccc(Cl)cc2)C(Cl)Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JWBOIMRXGHLCPP-UHFFFAOYSA-N
| melting_point = 76
| melting_high = 78
}}
Mitotane, sold under the brand name Lysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome.{{cite book| vauthors = Cavagnini F, Giraldi FP | chapter = Adrenal Causes of Hypercortisolism | veditors = Jameson JL, De Groot LJ |title=Endocrinology - E-Book: Adult and Pediatric| chapter-url= https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA1888|date=18 May 2010|publisher=Elsevier Health Sciences|isbn=978-1-4557-1126-0|pages=1888–}}{{cite journal | vauthors = Hahner S, Fassnacht M | title = Mitotane for adrenocortical carcinoma treatment | journal = Current Opinion in Investigational Drugs | volume = 6 | issue = 4 | pages = 386–394 | date = April 2005 | pmid = 15898346 }}{{cite book| vauthors = Dang C, Trainer PJ | chapter = Medical Management of Cushing's Syndrome| veditors = Bronstein MD |title=Cushing's Syndrome: Pathophysiology, Diagnosis and Treatment| chapter-url=https://books.google.com/books?id=5_ulQAM9OZYC&pg=PA156|date=1 October 2010|publisher=Springer Science & Business Media|isbn=978-1-60327-449-4|pages=156–}}{{cite book| vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA382|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=382–}} It is a derivative of the early insecticide DDT and an isomer of {{abbrlink|p,p'-DDD|dichlorodiphenyldichloroethane}} (4,4'-dichlorodiphenyldichloroethane) and is also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).{{cite web | title = Mitotane | url = https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4211 | work = PubChem | publisher = U.S. National Library of Medicine }}
Medical uses
Mitotane has been produced by Bristol Myers Squibb but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. In a 2007 retrospective study of 177 patients from 1985 to 2005 showed a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone.{{cite journal | vauthors = Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A | display-authors = 6 | title = Adjuvant mitotane treatment for adrenocortical carcinoma | journal = The New England Journal of Medicine | volume = 356 | issue = 23 | pages = 2372–2380 | date = June 2007 | pmid = 17554118 | doi = 10.1056/NEJMoa063360 | hdl-access = free | hdl = 2318/37317 }} The drug is also sometimes used in the treatment of Cushing's syndrome.
Side effects
The use of mitotane is unfortunately limited by side effects, which, as reported by Schteingart et al., include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).{{cite journal | vauthors = Schteingart DE, Motazedi A, Noonan RA, Thompson NW | title = Treatment of adrenal carcinomas | journal = Archives of Surgery | volume = 117 | issue = 9 | pages = 1142–1146 | date = September 1982 | pmid = 7115060 | doi = 10.1001/archsurg.1982.01380330010004 }}
Pharmacology
=Pharmacodynamics=
Mitotane is an inhibitor of the adrenal cortex. It acts as an inhibitor of cholesterol side-chain cleavage enzyme (P450scc, CYP11A1), and also of 11β-hydroxylase (CYP11B1), 18-hydroxylase (aldosterone synthase, CYP11B2), and 3β-hydroxysteroid dehydrogenase (3β-HSD) to a lesser extent.{{cite book| vauthors = Tzanela M, Vassiliadi DA, Tsagarakis S | chapter = Coincidental adrenal masses and adrenal cancer| veditors = Harris PE, Bouloux PM |title=Endocrinology in Clinical Practice | edition = Second | chapter-url= https://books.google.com/books?id=tZE-AwAAQBAJ&pg=PA216 |date=24 March 2014|publisher=CRC Press|isbn=978-1-84184-951-5|pages=216–}} In addition, mitotane has direct and selective cytotoxic effects on the adrenal cortex, via an unknown mechanism, and thereby induces permanent adrenal atrophy similarly to DDD.{{cite book| vauthors = Sojka WS, Raizer J| chapter = Neurologic Complications of Hormonal Chemotherapies | veditors = Lee EQ, Schiff D, Wen PY |title=Neurologic Complications of Cancer Therapy| chapter-url=https://books.google.com/books?id=52qyu5XPqM4C&pg=PA179 |date=28 September 2011|publisher=Demos Medical Publishing|isbn=978-1-61705-019-0|pages=179–}}{{cite book | vauthors = Kannan CR | chapter = Cushing's Syndrome |title=The Adrenal Gland| chapter-url= https://books.google.com/books?id=WqXSBwAAQBAJ&pg=PA160|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-1001-3|pages=160–}}
Chemistry
Analogues of mitotane include aminoglutethimide, amphenone B, and metyrapone.
History
Mitotane was introduced in 1960 for the treatment of adrenocortical carcinoma.
Society and culture
=Generic names=
Mitotane is the generic name of the medication and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}}.{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA697|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=697–}}
=Brand names=
Veterinary use
Mitotane is also used to treat Cushing's disease (pituitary-dependent Cushing's syndrome) in dogs. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.{{cite web|archive-date=21 October 2007|archive-url=https://web.archive.org/web/20071021093745/http://www.michvma.org/documents/MVC%20Proceedings/Nichols2.pdf|title=Canine Cushing's Syndrome: Diagnosis and Treatment Part 1: Typical, Atypical, and Pseudo-Cushing's Disease|url=http://www.michvma.org/documents/MVC%20Proceedings/Nichols2.pdf|vauthors=Nichols R}}
References
{{Reflist}}
Further reading
{{refbegin}}
- {{cite journal | vauthors = Komissarenko VP, Chelnakova IS, Mikosha AS | title = Effect of o,p-dichlorodiphenyldichloroethane and perthane in vitro on glutathione reductase activity in the adrenals of dogs and guinea pigs | doi = 10.1007/BF00800110 | year = 1978 | journal = Bulletin of Experimental Biology and Medicine | volume = 85 | issue = 2 | pages = 152–154| s2cid = 23181221 }}
{{refend}}
External links
- {{cite web | publisher = Government of Canada | title = Mitotane – information sheet | url = http://www.chemicalsubstanceschimiques.gc.ca/challenge-defi/summary-sommaire/batch-lot-12/53-19-0-eng.php | date = 16 October 2017 }}
- {{cite web | publisher = Environment Canada & Health Canada | url = http://www.ec.gc.ca/ese-ees/434E69F1-1490-4CD3-A0BB-4A15CA8D0313/RM%20Scope_B12%20-%2053-19-0_EN.pdf | archive-url = https://web.archive.org/web/20140810215750/http://www.ec.gc.ca/ese-ees/434E69F1-1490-4CD3-A0BB-4A15CA8D0313/RM%20Scope_B12%20-%2053-19-0_EN.pdf | archive-date = 10 August 2014 | title = RISK MANAGEMENT SCOPE for Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]- (Mitotane)] | date = July 2013 }}
{{Chemotherapeutic agents}}
{{Glucocorticoids and antiglucocorticoids}}
{{Portal bar | Medicine}}
{{Authority control}}
Category:3β-Hydroxysteroid dehydrogenase inhibitors
Category:11β-Hydroxylase inhibitors
Category:Aldosterone synthase inhibitors
Category:Cholesterol side-chain cleavage enzyme inhibitors
Category:Steroidogenesis inhibitors